Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia

作者：Trifilio Steven^*; Zhou Zheng; Altman Jessica; Frankfurt Olga; Pantiru Mihaela; Mehta Jayesh

来源：Leukemia Research, 2013, 37(8): 872-876.

DOI：10.1016/j.leukres.2013.05.006

• Etoposide
• Cyclophosphamide
• Acute myeloid leukemia
• Complete remissiona

Dose-intense etoposidecyclophosphamide (D-I ECy) without stem cell transplantation has been used in salvage regimens for the treatment of resistant acute myeloid leukemia(AML). Previous D-I ECy studies classified AML according to FAB-criteria, before cytogenetic risk was found to be a major determinant of prognosis. Currently the influence of karyotype on response to D-I ECy is unknown. Thus, an observational study was conducted in thirty four patients treated with D-I ECy for resistant AML. The results show this regimen is moderately effective in achieving CR in relapsed AML patients, including those with age >60 and poor cytogenetic risk category.

• 出版日期2013-8
• 单位西北大学